Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 419-425

  Kaira, Kyoichi ^a   Serizawa, Masakuni ^a   Koh, Yasuhiro ^a   Miura, Satoru ^a   Kaira, Rieko ^a   Abe, Masato ^a   Nakagawa, Kazuo ^a   Ohde, Yasuhisa ^a   Okumura, Takehiro ^a   Murakami, Haruyasu ^a   Tsuya, Asuka ^a   Nakamura, Yukiko ^a   Naito, Tateaki ^a   Takahashi, Toshiaki ^a   Kondo, Haruhiko ^a   Nakajima, Takashi ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

DPD; OPRT; Prognosis; Thymic epithelial tumor; TS

Indexed keywords

CD34 ANTIGEN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOMA; THYMUS CANCER; THYMUS CARCINOMA;

AGED; AGED, 80 AND OVER; ANTIGENS, CD34; CARCINOMA; CELL LINE, TUMOR; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROVESSELS; MIDDLE AGED; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROGNOSIS; THYMIDYLATE SYNTHASE; THYMUS NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80755130096     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.001     Document Type: Article

References (29)

1. Engels E.A., Pfeiffer R.W. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003, 105:546-551.
2. Rosai J., Sobin L.H. Histological typing of tumours of the thymus, international histological classification of tumours 1999, Springer, New York, p. 1-59. 2nd ed.
3. Travis W.D., Brambillia E., Muller-Hermelink H.K. WHO classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart 2004, IARC Press, Lyon.
4. Koizumi T., Takayabashi Y., Yamagishi S., Tsushima K., Takamizawa A., tsukadaira A., et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002, 25:266-268.
5. Yok K., Goto K., Ishii G., Niho S., Ohmatsu H., Kubota K., et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003, 98:926-931.
6. Igawa S., Murakami H., Takahashi T., Nakamura Y., Tsuya A., Naito T., et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010, 67:194-197.
7. Ono A., Naito T., Yamamoto N. S-1 treatment for chemorefractory thymic carcinoma. J Thorac Oncol 2008, 3:1076.
8. Shirasaka T., Shimamato Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7:548-557.
9. Kawahara M., Furuse K., Segawa Y., Yoshimori K., Matsui K., Kudoh S., et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001, 85:939-943.
10. Nakano J., Huang C., Liu D., Masuya D., Nakashima T., Yokomise H., et al. Evaluation of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006, 95:607-615.
11. Masaoka A., Monden Y., Nakahara K., Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981, 48:2485-2492.
12. 18F]-fluoro-2-deoxy-d-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010, 28:3746-3753.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Eisenhauer E.A., Wanders J., Kaplan R.S., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
14. Johnston P.G., Lenz H.J., Leichman C.G. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumor. Cancer Res 1995, 55:1407-1412.
15. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
16. Lenz H., Leichman C.G., Danenberg K.D., Danenberg P.V., Groshen S., Cohen H., et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1995, 14:176-182.
17. Ceppi P., Volante M., Ferrero A., Righi L., Rapa I., Rosas R., et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008, 14:1059-1064.
18. Ibe T., Shimizu K., Nakano T., Kakegawa S., Kamiyoshihara M., Nakajima T., et al. High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes. J Surg Oncol 2010, 102:11-17.
19. Sasaki H., Fukai I., Kiriyama M., Kaji M., Yano M., Yamakawa Y., et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma. Surg Today 2003, 33:83-88.
20. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. J Surg Oncol 2009, 99:433-438.
21. Giovannetti E., Backus H.H., Wounters D., Ferreira C.G., van Houten V.M., Brakenhoff R.H., et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007, 96:769-775.
22. Hamada C., Tanaka F., Ohta M., Fujimura S., Kodama K., Imaizumi M., et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005, 23:4999-5007.
23. Ishihama H., Chida M., Araki O., Karube Y., Seki N., Tamura M., et al. Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. Jpn J Clin Oncol 2009, 39:33-36.
24. Harada K., Kawashima Y., Yoshida H., Sato M. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1. Oncol Rep 2006, 15:1417-1423.
25. Lee S., Park Y.H., Kim K.H., Cho E.Y., Ahn Y.C., Kim K., et al. Thymidylate synthase, thymidine phosphorylase, and excision repair-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. Br J Cancer 2010, 7:845-851.
26. Yoshitomi I., Kawasaki G., Yanamoto S., Mizuo A. Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the duhydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil. Oral Oncol 2006, 42:880-887.
27. Mizutani Y., Wada H., Fukushima M., Yoshida O., Nakanishi H., Li Y.N., et al. Prognostic significance of orotate phosphoribosyl transferase activity in bladder carcinoma. Cancer 2004, 100:723-731.
28. Tagawa T., Ohta M., Kuwata T., Awaya H., Ishida T. S-1 plus cisplatin chemotherapy with concurrent radiation for thymic basaloid carcinoma. J Thorac Oncol 2010, 5:572-573.
29. Fukui Y., Oka T., Nagayama S., Danenberg P.V., Danenberg K.D., Fukushima M. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 2008, 22:709-716.